Evaluation of acitretin side effects on Iraqi psoriatic patients
Article Sidebar
Main Article Content
Abstract
Acitretin is the major metabolite of etretinate , an aromatic retinoid that formerly was approved for Psoriasis by exhibiting vitamin A activity. Acitretin was wildly used to improve plaque psoriasis and also for postural psoriasis and erthrodemic psoriasis .The present study focus on the evaluation of the common side effects of acitretin which makes a wide hesitation for Iraqi dermatologists to use it in treatement of psoriasis. Twenty psoriatic outpatient were treated with a dose of 25mg/ day for three continuous months in outpatient clinic of al- noor hospital during 2009 , their lipid profiles , liver and kidney function tests before starting treatment with acitretin considered as a control values. It was noticed that AST level increased significantly during 2nd and 3rd months of treatment and there is no significant change in S. Creatinine and BUN while TG increased significantly in 2nd and 3rd months of treatment.Cholesterol increased in the 3rd month of treatment. There is other important factors should be consider before evaluation the physiological changes may be caused by acitretin like smoking , alcohol intake , obesity and genetic association between psoriasis and other physiological change. However the changes that caused by administration of acitretin were relatively acceptable and not preventive measurement , but continuous monitoring (of TG , cholesterol , liver and kidney function test) still required regularly.
Downloads
Article Details
How to Cite
References
1. Nicholas A. Boon NR Colledge BR and Walker D(2007). principles and practice of medicine, 2007, 20th edition:Pp 1287.
2. Hunter JAA Savin JA and Dahl MV(2002). Clinical dermatology.3rd edition by Blackwell Science Ltd:pp 49.
3. Laurence B Keith P Donald B and lain B(2008). Goodman and Gilman manual of pharmacology and therapeutic, 11th edition: Pp1077-1080.
4. Bertani G Katzung (2007). Basic and clinical pharmacology.Tenth edition:Pp 999-1000.
5. Richard A and Harvey PO(2000).. Ghampe.Lippincott's pharmacology, Mary J Mycek 3rd edition.
6. Louis Missouri S Daniel HC Andrew J and krainik MD. The Washington manual of medical therapeutic, 32nd edition:Pp 591.
7. Habiefe (2004).Clinical dermatology , 2004, 4th edition :Pp 209.
8. Elizabeth A and Martin MA(200). Oxford medical dictionary. 3rd edition:Pp 569.
9. Whiting-O’Keefe QE Fye KH and Sack KD(1991). Methotrexate and histological hepatic abnormalities: a meta-analysis. Am J Med (1991) 90:711–6.
10. Tilling L Townsend S and David J(2006). Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investing. 26:55–62.
11. Gottlieb AB Dann F and Menter A(2008). Psoriasis and the metabolic syndrome. J Drugs Dermatol 7: 563-572.
12. Gottlieb AB Chao C and Dann F(2007). Psoriasis comorbidities. J Dermatol Treatment 19: 5-21.
13. Mallbris L Granath F and Hamsten A(2006). Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad. Dermatol. 54: 614-21.
14. gotto AM Jr(1992). Management of lipid and lipoprotein disorder , manual of lipid disorder . Baltimore : Williams and Wilkins .
15. Henseler T and Christopher's E(1995). Disease concomitance in psoriasis. J Am Acad Dermatol. 32:982–986.
16. Herron MD Hinckley M and Hoffman MS(2005). Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 141:1527–34.
17. Setty AR Curhan G and Choi HK(2007). Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med.167:1670–5.
18. Gottlieb AB Chao C and Dann F(2007). Psoriasis comorbidities. J Dermatol Treatment 19: 5-21.
19. A Haas RW and del Rincon I(2005).. Paradoxical effect of body mass index on survival in rheumatoid arthritis. Arch Intern Med.165: 1624–1629.
20. Sterry W Strober BE and Menter A(2007). Obesity in psoriasis: the metabolic, clinical and therapeutic implications.Br J Dermatol .157:649–655.
21. Sommer DM Jenisch S Suchan M Christophers E and Weichenthal M(2006). Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res.298:321–328.
22. Mallbris L Akre O Granath F Yin L Lindelöf B Ekbom A and Ståhle-Bäckdahl M(2004). Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol.19:225–230.
23. Shoelson SE Lee and Goldfine AB(2006). Inflammation and insulin resistance. J Clin Invest.116:1793–1801.
24. Baratta R Amato S Degano C Farina MG Patane G Vigneri R and Frittitta L (2004).Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endo Metab. 89: 2665–2671.
25. Pittas AG Joseph NA and Greenberg AS(2004). Adipocytokines and insulin resistance. J Clinl Endo Metab. 89: 447–452.
26. Goldstein BJ and Scalia R(2004). Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clinl Endo Metab. 89: 2563–2568.
27. -Pereira P Santos-Silva A Rebelo I Figueiredo A and Quintanilha A(2001). Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta . 303: 33–39.
28. Mallbris L Granath F Hamsten A and Ståhle M(2006). Psoriasis is associated with lipid abnormalities at the onset of skin disease, J Am Acad. Dermatol.54:614–621.
29. Fasshauer M and Paschke R(2003).. Regulation of adipocytokines and insulin resistance.Diabetologia.46: 1594–1603.
30. Shetty GK Economides PA Horton ES Mantzoros CS and Veves A(2004). Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 27: 2450–2457.
31. Bonet ML Ribot J and Palou A(2004). Modulation of resistin expression by retinoic acid and vitamin A status. Diabetes.53: 882–889.
32. Zhang Y Matheny M Zolotukhin S Tumer N and Scarpace PJ(2002). Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting. Biochimica et Biophysica Acta . 1584: 115–122.
33. Berthou L Staels B Saldicco I Berthelot K Casey J Fruchart JC,Denefle P and Branellec D(1994). Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression. Arteriosclerosis, Thrombosis and Vascular Biology. 14: 1657–1664.
34. Neiman AI Shin DB Wang X Margolis DJ Troxel AB Gelfand(2006) . Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 55:829–835.
35. Herron MD Hinckley M Hoffman M Papenfuss J Hansen CB Callis KP and Krueger GC(2005). Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 141:1527–1534.
36. Lowe ME Rosenblum JL and Strauss AW(1989). Cloning and characterization of human pancreatic lipase cDNA. J Biol Chem. 264: 20042-20048.
37. Winkler FK D’Arcy A and Hunziker W(1990). Structure of human pancreatic lipase. Nature. 343: 771-774.